• Explore /
  • Poster
  • / TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

Abstract Video & Slides Poster

Authors

Stuart Wong

Stuart J. Wong

Medical College of Wisconsin, Milwaukee, WI

Stuart J. Wong , Pedro A. Torres-Saavedra , Nabil F. Saba , George Shenouda , Jeffrey Bumpous , Robert E. Wallace , Christine H. Chung , Adel K. El-Naggar , Clement K Gwede , Barbara Burtness , Paul Tennant , Neal E. Dunlap , Loren K. Mell , Sharon Spencer , William A. Stokes , Min Yao , Darrion L Mitchell , Jonathan Harris , Walter J Curran , Quynh-Thu Le

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6014)

DOI

10.1200/JCO.2021.39.15_suppl.6014

Abstract #

6014

Abstract Disclosures